Disruption in the field of incontinence: MedTech startup inContAlert raises EUR 1.5 million

The MedTech startup inContAlert, headquartered in Bayreuth, successfully closed its pre-seed financing round of EUR 1.5 million in total. The round is led by High-Tech Gründerfonds, Bayern Kapital, and Carma Fund, accompanied by renowned business angels from the medical technology domain.

In Germany alone, 2.2 million individuals could benefit from the technology. The startup develops a sensor-based solution to improve quality of life for those dealing with incontinence. Positioned non-invasively two finger-widths above the pubic bone, the sensor continuously gathers data related to bladder activity. This data is analyzed via machine learning and deep learning algorithms, while a dedicated mobile application provides insights into optimal timings for bladder voiding and timely notifications when a predefined filling level is reached.

inContAlert’s technology primarily serves patients dealing with neurogenic bladder disorders, including spinal cord injuries, multiple sclerosis, bladder cancer, and Parkinson’s disease. Looking ahead, the technology could also help children struggling with bedwetting issues. Through its emphasis on on-demand emptying, reliance on diapers or catheters can potentially be minimized while lowering the risk of urinary tract and kidney damage.

The allocated investment will be directed toward further studies, obtaining the CE mark as a medical device, and preparing for market entry.

The original announcement also includes statements from Dr. Jannik Lockl, Jakob Lilienweiss at HTGF, Markus Mrachacz at Bayern Kapital, and Christian Leikert at Carma Fund on quality-of-life impact, care efficiency, and the founding team’s capabilities, alongside detailed background on each investor.